Pseudallescheria boydii with Aspergillus fumigatus and Aspergillus terreus in a Critically Ill Hematopoietic Stem Cell Recipient with ARDS

详细信息    查看全文

• 作者：Tobias Lahmer ; Marlena Messer ; Ursula Ehmer ; Stefan Eser ; Analena Beitz…
• 关键词：Pseudallescheria boydii ; Critically ill ; Aspergillus terreus ; Aspergillus fumigatus
• 刊名：Mycopathologia
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：181
• 期：3-4
• 页码：267-271
• 全文大小：344 KB
• 参考文献：1.Panackal AA, Marr KA. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med. 2004;25:171–81.CrossRef PubMed
  2.Katragkou A, Dotis J, Kotsiou M, Tamiolaki M, Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses. 2007;50:412–21.CrossRef PubMed
  3.Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis. 1992;14:1027–33.CrossRef PubMed
  4.Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870.CrossRef PubMed
  5.Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol. 2010;150:406.PubMed
  6.Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205.CrossRef PubMed
  7.Daben R, de Lucas M, Cuesta L, et al. Imaging findings of pulmonary infection caused by Scedosporium prolificans in a deep immunocompromised patient. Emerg Radiol. 2008;15:47–9.CrossRef
  8.Koga T, Kitjima T, Tanaka R, et al. Chronic pulmonary scedosporiosis simulating aspergillosis. Respirology. 2005;10:682–4.CrossRef PubMed
  9.Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24:247–80.CrossRef PubMed PubMedCentral
  10.Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688.CrossRef PubMed
  11.Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol. 2008;15:1760.CrossRef PubMed PubMedCentral
  12.Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer. 2007;110:830.CrossRef PubMed
  13.Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol. 2010;48:1255.CrossRef PubMed PubMedCentral
  14.Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1→3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957.CrossRef PubMed PubMedCentral
  15.Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750.CrossRef PubMed
  16.Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012; 54:633.
  17.Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1–3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52:2328.CrossRef PubMed PubMedCentral
  18.Cuétara MS, Alhambra A, Moragues MD, González-Elorza E, Pontón J, Palacio A. Detection of (1→3)-β-d-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol. 2009;16(3):423–6.CrossRef PubMed PubMedCentral
  19.Nomdedeu J, Brunet S, Martino R, Altes A, Ausina V, Domingo-Albos A. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis. 1993;16:731–3.CrossRef PubMed
  20.Walsh M, White L, Atkinson K, Enno A. Fungal Pseudoallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Aust N Z J Med. 1992;22:265–8.CrossRef PubMed
  21.Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–8.CrossRef PubMed PubMedCentral
  22.Tong SY, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2007;9:241–3.CrossRef PubMed
  
• 作者单位：Tobias Lahmer (1)
  Marlena Messer (1)
  Ursula Ehmer (1)
  Stefan Eser (1)
  Analena Beitz (1)
  Lisa Fekecs (1)
  Roland M. Schmid (1)
  Wolfgang Huber (1)
  
  1. II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675, Munich, Germany
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Medical Microbiology
  Plant Sciences
  Microbial Ecology
  
• 出版者：Springer Netherlands
• ISSN：1573-0832

文摘

Pseudallescheria boydii is a fungal organism known to affect immunocompromised patients. This organism is known to cause, in severe cases, invasive infection of various organs such as the central nervous, cardiovascular, and respiratory systems. We report an unusual case of pulmonary P. boydii pneumonia in an immunocompromised critically ill patient with a co-infection of Aspergillus fumigatus and Aspergillus terreus with ARDS. This case highlights the importance of a high index of suspicion for superimposed fungal infections in patients who are critically ill and immunocompromised. Uncommon fungal pathogens should be considered in the differential diagnosis of respiratory failure, especially if diagnostic markers such as galactomannan (from BAL and serum) or 1,3-beta-d-glucan are elevated. Further diagnostic interventions are warranted when insufficient clinical improvement is observed to prevent treatment failure and adverse outcomes.